US 11,753,458 B2
CTLA-4 variant immunomodulatory proteins and uses thereof
Lawrence Evans, Seattle, WA (US); Joseph L. Kuijper, Seattle, WA (US); and Ryan Swanson, Seattle, WA (US)
Assigned to Alpine Immune Sciences, Inc., Seattle, WA (US)
Appl. No. 16/755,072
Filed by Alpine Immune Sciences, Inc., Seattle, WA (US)
PCT Filed Oct. 9, 2018, PCT No. PCT/US2018/055095
§ 371(c)(1), (2) Date Apr. 9, 2020,
PCT Pub. No. WO2019/074983, PCT Pub. Date Apr. 18, 2019.
Claims priority of provisional application 62/733,615, filed on Sep. 19, 2018.
Claims priority of provisional application 62/613,379, filed on Jan. 3, 2018.
Claims priority of provisional application 62/570,619, filed on Oct. 10, 2017.
Prior Publication US 2020/0308249 A1, Oct. 1, 2020
Int. Cl. C07K 14/705 (2006.01); A61K 47/65 (2017.01); A61P 19/02 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/00 (2006.01)
CPC C07K 14/70521 (2013.01) [A61K 35/17 (2013.01); A61K 47/65 (2017.08); A61P 19/02 (2018.01); C07K 14/7051 (2013.01); C12N 5/0637 (2013.01); C12N 15/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01)] 31 Claims
 
1. A variant CTLA-4 polypeptide, comprising an IgV domain or a specific binding fragment thereof, wherein the variant CTLA-4 polypeptide comprises one or more amino acid modifications in an unmodified CTLA-4 polypeptide or a specific binding fragment thereof corresponding to position(s) selected from among 29, 53, 56, 58, 82, 87, and 98, with reference to positions set forth in SEQ ID NO:2 and wherein the sequence includes L63P and Y105L.